Roche named and shamed for Code breaches
pharmafile | September 2, 2008 | News story | Sales and Marketing |Â Â ABPI, ethicsÂ
Roche has been named and shamed in the medical press for breaching the ABPI's Code of Practice.
Adverts about the case appeared in the British Medical Journal and The Pharmaceutical Journal last week highlighting the pharma company's behaviour.
This led in July to Roche being suspended from the ABPI for at least six months after an investigation found the company had brought discredit on the pharmaceutical industry.
The case concerned Roche's inappropriately supply of Xenical to the operator of several private diet clinics between 2003 and 2005.
The individual concerned was not a health professional and so the company was found guilty of selling a prescription only medicine to a member of the public.
Roche had also agreed to give £55,000, which was already paid in part, to the same person to purchase another private diet clinic.
This breached the Code on three separate counts, and Roche will now have to pass an external audit of its procedures before it can regain its membership.
Related Content

The November 2020 issue of Pharmafocus is available to read free online now!
The latest monthly edition of Pharmafocus is available to read for free online now!

UK life sciences industry does not want no-deal Brexit, says ABPI Chief
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a …

ABPI Chief Executive Mike Thompson to retire by the end of 2019
The Association of the British Pharmaceutical Industry (ABPI) has announced that its Chief Executive Mike …






